# Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

> **NCT03330990** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Entrectinib
- **DRUG:** Midazolam Hydrochloride

## Key facts

- **NCT ID:** NCT03330990
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03330990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03330990, "Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03330990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*